Mtp kit and procedure
MTP kit mifepristone misoprostol medical abortion procedure dosage
| Tablet | Dose | Quantity |
|---|---|---|
| Mifepristone (RU-486) | 200 mg | 1 tablet |
| Misoprostol | 200 mcg each | 4 tablets (total 800 mcg) |
| Day | Drug | Dose | Route |
|---|---|---|---|
| Day 1 | Mifepristone | 200 mg | Oral |
| Day 2-3 (36-48 hrs later) | Misoprostol | 800 mcg | Vaginal / Buccal / Sublingual |
| Day | Drug | Dose | Route |
|---|---|---|---|
| Day 1 | Mifepristone | 600 mg | Oral |
| Day 3 | Misoprostol | 400 mcg | Oral |
| Drug | Common Side Effects |
|---|---|
| Mifepristone | Nausea, cramping, spotting |
| Misoprostol | Heavy bleeding, uterine cramping, diarrhea, chills, fever, nausea, vomiting |
Important: The MTP Kit must be used only under the supervision of a registered medical practitioner. Self-administration without medical guidance is unsafe and illegal in India under the MTP Act.
Mandatory Investigations
mandatory investigations before MTP medical termination of pregnancy India protocol
| Investigation | Purpose |
|---|---|
| Urine Pregnancy Test (UPT) | Confirms pregnancy before initiating any procedure |
| Serum β-hCG | When UPT is equivocal; also baseline for follow-up if needed |
| Investigation | Purpose |
|---|---|
| Transvaginal / Abdominal Ultrasonography (USG) | - Confirms intrauterine pregnancy (rules out ectopic) - Determines exact gestational age (weeks) - Rules out undiagnosed adnexal mass - Rules out hydatidiform mole - Detects multiple pregnancies |
USG is the single most important mandatory investigation before MTP. Ectopic pregnancy is a hard contraindication - administering MTP kit in an ectopic pregnancy will NOT terminate it and may cause life-threatening rupture.
| Investigation | Purpose |
|---|---|
| Hemoglobin (Hb) | Assess for pre-existing anemia; significant bleeding is expected post-MTP |
| Blood Group (ABO typing) | Required in case emergency transfusion is needed |
| Rh (D) Typing | If Rh-negative, anti-D immunoglobulin (300 mcg) must be given within 72 hours of MTP to prevent Rh isoimmunization in future pregnancies |
| Bleeding Time (BT) / Clotting Time (CT) or Coagulation screen (PT/aPTT) | Rule out hemorrhagic disorders (a contraindication to mifepristone) |
| Investigation | Purpose |
|---|---|
| Urine Routine & Microscopy | Detect UTI, proteinuria, or renal disease that may affect management |
| Investigation | Purpose |
|---|---|
| Blood Pressure / Pulse / Temperature | Baseline vitals; hypertension affects prostaglandin safety |
| Pelvic Examination | Size of uterus consistent with gestational age; rule out pelvic infection or IUD in situ |
| STI/Vaginal swab (if clinically indicated) | Rule out active genital tract infection before surgical MTP |
| # | Investigation | Why Mandatory |
|---|---|---|
| 1 | Urine Pregnancy Test | Confirms pregnancy |
| 2 | USG (transvaginal/abdominal) | Rules out ectopic, confirms GA |
| 3 | Hemoglobin | Pre-anemia, anticipate blood loss |
| 4 | Blood Group + Rh typing | Transfusion prep + anti-D need |
| 5 | BT/CT or Coagulation screen | Rules out bleeding disorder |
| 6 | Urine routine | Baseline renal/infection status |
| 7 | Vitals (BP, Pulse) | Baseline + prostaglandin safety |
All investigations should be completed, documented, and reviewed before prescribing the MTP kit. The MTP Act (India, 1971, amended 2021) requires that the procedure be performed only at certified facilities by a registered medical practitioner - these investigations form the foundation of safe, legal practice.